Login to Your Account



Comeback Kid

Medivation Shares up 140% On Positive MDV3100 Results

By Tom Wall
BioWorld Today Contributing Writer

Friday, November 4, 2011

Medivation Inc. stock doubled and then some following an announcement by the San Francisco-based biotech and partner Astellas Pharma Inc., of Tokyo, that results from an interim analysis of the Phase III AFFIRM trial of MDV3100 in men with advanced prostate cancer were so positive that the independent data monitoring committee recommended the trial be stopped and MDV3100 offered to the men who received placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription